How insulin engages its primary binding site on the insulin receptor

Journal name:
Nature
Volume:
493,
Pages:
241–245
Date published:
DOI:
doi:10.1038/nature11781
Received
Accepted
Published online

Insulin receptor signalling has a central role in mammalian biology, regulating cellular metabolism, growth, division, differentiation and survival1, 2. Insulin resistance contributes to the pathogenesis of type 2 diabetes mellitus and the onset of Alzheimer’s disease3; aberrant signalling occurs in diverse cancers, exacerbated by cross-talk with the homologous type 1 insulin-like growth factor receptor (IGF1R)4. Despite more than three decades of investigation, the three-dimensional structure of the insulin–insulin receptor complex has proved elusive, confounded by the complexity of producing the receptor protein. Here we present the first view, to our knowledge, of the interaction of insulin with its primary binding site on the insulin receptor, on the basis of four crystal structures of insulin bound to truncated insulin receptor constructs. The direct interaction of insulin with the first leucine-rich-repeat domain (L1) of insulin receptor is seen to be sparse, the hormone instead engaging the insulin receptor carboxy-terminal α-chain (αCT) segment, which is itself remodelled on the face of L1 upon insulin binding. Contact between insulin and L1 is restricted to insulin B-chain residues. The αCT segment displaces the B-chain C-terminal β-strand away from the hormone core, revealing the mechanism of a long-proposed conformational switch in insulin upon receptor engagement. This mode of hormone–receptor recognition is novel within the broader family of receptor tyrosine kinases5. We support these findings by photo-crosslinking data that place the suggested interactions into the context of the holoreceptor and by isothermal titration calorimetry data that dissect the hormone–insulin receptor interface. Together, our findings provide an explanation for a wealth of biochemical data from the insulin receptor and IGF1R systems relevant to the design of therapeutic insulin analogues.

At a glance

Figures

  1. Structure of insulin, insulin receptor and the site 1 complexes.
    Figure 1: Structure of insulin, insulin receptor and the site 1 complexes.

    a, Insulin. InsA, A chain; InsB, B chain. b, Insulin receptor. CR, Cys-rich domain; FnIII-1, FnIII-2, FnIII-3, first, second and third fibronectin type III domains; ID, insert domain; L1, L2, first and second leucine-rich-repeat domains; TK, tyrosine kinase; TM, JM, transmembrane and juxtamembrane segments. c, d, IR310.T and IR593.αCT domain structure, respectively. e, f, Insulin-bound site 1 in complexes A and D, respectively. Blue, red spheres, observed chain termini; orange sphere, FnIII-1–αCT junction. g, Overlay of insulin-bound site 1 in complexes A (coloured as in e), B (red), C (green) and D (white). h, Sample 2FobsFcalc map volumes (Bsharp = −160Å2; contours = 1.1–1.5σ) for complex A.

  2. The insulin-site 1 interaction.
    Figure 2: The insulin–site 1 interaction.

    a, Altered disposition of αCT with respect to that in apo-insulin receptor12. b, Superposition (via the A- and B-chain helices) of receptor-free insulin onto the insulin–site 1 complex, indicating steric clash of the B-chain C-terminal segment (green) with αCT. See also Supplementary Fig. 3a. c, Interaction (at the bulk side-chain level of detail) between αCT(704–719) and insulin. View direction is parallel to L1–β2 surface (cyan); white shading shows insulin surface. d, e, Interaction (at the bulk side-chain level of detail) between L1 and αCT and between L1 and insulin B-chain helix, respectively. Panels based on complex A.

  3. Insulin interactions in L1-CR-L2 mini-insulin receptor and holo-insulin receptor.
    Figure 3: Insulin interactions in L1–CR–L2 mini-insulin receptor and holo-insulin receptor.

    a, Helical wheel representation of ITC-derived insulin affinities for IR485 in the presence of Ala-substituted αCT(704–719) (red, >100× reduction upon Ala substitution; green, >10× reduction; grey, <10× reduction; open circle, not determined). b, Reducing gel autoradiograms obtained from holo-insulin receptor after photo-crosslinking of αCT helix to bound 125I-[TyrA14]-insulin. Arrowed band indicates crosslinked insulin receptor α-chain–insulin A chain. Colours indicate crosslinking efficiency (red, strong; green, medium; blue, weak; grey, none). c, d, Qualitative crosslinking efficiency from b mapped onto αCT segment within the site 1 complexes. e, Helical wheel representation of crosslinking data presented in bd.

Accession codes

Primary accessions

References

  1. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nature Rev. Mol. Cell Biol. 7, 8596 (2006)
  2. Cohen, P. The twentieth century struggle to decipher insulin signalling. Nature Rev. Mol. Cell Biol. 7, 867873 (2006)
  3. Talbot, K. et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 13161338 (2012)
  4. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Rev. Cancer 12, 159169 (2012)
  5. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 11171134 (2010)
  6. Adams, M. J. et al. Structure of rhombohedral 2 zinc insulin crystals. Nature 224, 491495 (1969)
  7. McKern, N. M. et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443, 218221 (2006)
  8. Seino, S. & Bell, G. I. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Commun. 159, 312316 (1989)
  9. Schäffer, L. A model for insulin binding to the insulin receptor. Eur. J. Biochem. 221, 11271132 (1994)
  10. De Meyts, P. Insulin and its receptor: structure, function and evolution. Bioessays 26, 13511362 (2004)
  11. Ward, C. W. & Lawrence, M. C. Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor. Bioessays 31, 422434 (2009)
  12. Smith, B. J. et al. Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists. Proc. Natl Acad. Sci. USA 107, 67716776 (2010)
  13. Ward, C. W. & Lawrence, M. C. Similar but different: ligand-induced activation of the insulin and epidermal growth factor receptor families. Curr. Opin. Struct. Biol. 22, 360366 (2012)
  14. Kiselyov, V. V., Versteyhe, S., Gauguin, L. & De Meyts, P. Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric binding and activation. Mol. Syst. Biol. 5, 243 (2009)
  15. Whittaker, L., Hao, C., Fu, W. & Whittaker, J. High-affinity insulin binding: insulin interacts with two receptor ligand binding sites. Biochemistry 47, 1290012909 (2008)
  16. Lou, M. et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc. Natl Acad. Sci. USA 103, 1242912434 (2006)
  17. Garrett, T. P. et al. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 394, 395399 (1998)
  18. Jiráček, J. et al. Implications for the active form of human insulin based on the structural convergence of highly active hormone analogues. Proc. Natl Acad. Sci. USA 107, 19661970 (2010)
  19. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 10301033 (2012)
  20. Evans, P. Resolving some old problems in protein crystallography. Science 336, 986987 (2012)
  21. Brünger, A. T., DeLaBarre, B., Davies, J. M. & Weis, W. I. X-ray structure determination at low resolution. Acta Crystallogr. D 65, 128133 (2009)
  22. Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368380 (2012)
  23. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355367 (2011)
  24. Hua, Q. X., Shoelson, S. E., Kochoyan, M. & Weiss, M. A. Receptor binding redefined by a structural switch in a mutant human insulin. Nature 354, 238241 (1991)
  25. Whittaker, J. et al. α-Helical element at the hormone-binding surface of the insulin receptor functions as a signaling element to activate its tyrosine kinase. Proc. Natl Acad. Sci. USA 109, 1116611171 (2012)
  26. Kristensen, C., Wiberg, F. C. & Andersen, A. S. Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors. Role of C-terminal of receptor α subunit. J. Biol. Chem. 274, 3735137356 (1999)
  27. Xu, B. et al. Diabetes-associated mutations in insulin: consecutive residues in the B chain contact distinct domains of the insulin receptor. Biochemistry 43, 83568372 (2004)
  28. Xu, B. et al. Decoding the cryptic active conformation of a protein by synthetic photo-scanning. Insulin inserts a detachable arm between receptor domains. J. Biol. Chem. 284, 1459714608 (2009)
  29. Xu, B. et al. Diabetes-associated mutations in insulin identify invariant receptor contacts. Diabetes 53, 15991602 (2004)
  30. Weiss, M. S. Global indicators of X-ray data quality. J. Appl. Cryst. 34, 130135 (2001)
  31. Hoogenboom, H. R. et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19, 41334137 (1991)
  32. Stanley, P. Chinese hamster ovary cell mutants with multiple glycosylation defects for production of glycoproteins with minimal carbohydrate heterogeneity. Mol. Cell. Biol. 9, 377383 (1989)
  33. Soos, M. A. et al. Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem. J. 235, 199208 (1986)
  34. Evan, G. I., Lewis, G. K., Ramsay, G. & Bishop, J. M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5, 36103616 (1985)
  35. Denley, A. et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol. Endocrinol. 18, 25022512 (2004)
  36. Markussen, J., Halstrom, J., Wiberg, F. C. & Schäffer, L. Immobilized insulin for high capacity affinity chromatography of insulin receptors. J. Biol. Chem. 266, 1881418818 (1991)
  37. Žáková, L. et al. Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity. Biochemistry 47, 58585868 (2008)
  38. McPhillips, T. M. et al. Blu-ice and the distributed control system: software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 9, 401406 (2002)
  39. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D 66, 133144 (2010)
  40. Collaborative Computing Project The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760763 (1994)
  41. McCoy, A. J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D 63, 3241 (2007)
  42. Bricogne, G. et al. BUSTER version 2.10 (Global Phasing Ltd, 2011)
  43. Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D 60, 22102221 (2004)
  44. Kleywegt, G. J. & Jones, T. A. Template convolution to enhance or detect structural features in macromolecular electron-density maps. Acta Crystallogr. D 53, 179185 (1997)
  45. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comp. Chem. 25, 16051612 (2004)
  46. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 21262132 (2004)
  47. Jones, T. A. & Thirup, S. Using known substructures in protein model building and crystallography. EMBO J. 5, 819822 (1986)
  48. Lüthy, R., Bowie, J. U. & Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 356, 8385 (1992)
  49. Sparrow, L. G. et al. N-linked glycans of the human insulin receptor and their distribution over the crystal structure. Proteins Struct. Funct. Bioinform. 71, 426439 (2008)
  50. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D 66, 2225 (2010)
  51. Hua, Q. X. et al. Enhancing the activity of a protein by stereospecific unfolding. The conformational life cycle of insulin and its evolutionary origins. J. Biol. Chem. 248, 1458614596 (2009)
  52. Menting, J. G., Ward, C. W., Margetts, M. B. & Lawrence, M. C. A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor α-chain C-terminal peptide and the site 1 insulin mimetic peptides. Biochemistry 48, 54925500 (2009)

Download references

Author information

  1. These authors contributed equally to this work.

    • John G. Menting &
    • Jonathan Whittaker

Affiliations

  1. Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia

    • John G. Menting,
    • Mai B. Margetts,
    • Geoffrey K.-W. Kong,
    • Brian J. Smith,
    • Colin W. Ward &
    • Michael C. Lawrence
  2. Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA

    • Jonathan Whittaker,
    • Linda J. Whittaker &
    • Michael A. Weiss
  3. Department of Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia

    • Brian J. Smith
  4. York Structural Biology Laboratory, Department of Chemistry, University of York, York YO10 5DD, UK

    • Christopher J. Watson,
    • Guy G. Dodson &
    • Andrzej M. Brzozowski
  5. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., 16610 Prague, Czech Republic

    • Lenka Žáková,
    • Emília Kletvíková &
    • Jiří Jiráček
  6. Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA

    • Shu Jin Chan &
    • Donald F. Steiner
  7. Department of Medical Biology, University of Melbourne, Royal Parade, Parkville, Victoria 3010, Australia

    • Michael C. Lawrence
  8. Deceased.

    • Guy G. Dodson

Contributions

J.G.M. and J.W. contributed equally to the paper. J.G.M. purified and crystallized samples, collected data and performed the ITC study; J.W. and L.J.W. performed receptor photo-crosslinking experiments; M.B.M. performed molecular biology, cell culture and crystallization experiments; S.J.C. performed insulin photo-crosslinking experiments; G.K.-W.K. and C.J.W. performed crystallography experiments; B.J.S. performed calculations; E.K., L.Z. and J.J. prepared insulin analogues; C.W.W., M.A.W., J.W., D.F.S., S.J.C., J.G.M. and M.C.L. designed the experiments and analysed data. C.W.W., M.A.W., A.M.B., G.G.D. and M.C.L. wrote the paper. All authors discussed the results and commented on the manuscript.

Competing financial interests

J.W. is a consultant to Thermalin Diabetes, LLC; J.W. and L.J.W. own stock in Novo-Nordisk A/S; M.A.W. owns stock in Thermalin Diabetes, LLC, serves as its Chief Scientific Officer, and is a member of its Board of Directors, and has also served as a consultant to Merck and DEKA R&D Corporation. M.C.L. has received honoraria and/or travel funding for seminars delivered at Novo-Nordisk A/S and Sanofi-Aventis.

Corresponding authors

Correspondence to:

Atomiccoordinates andstructure factors for complexes A, B,Cand D have been deposited with the Protein Data Bank under accession codes 3W11, 3W12, 3W13 and 3W14, respectively.

Author details

Supplementary information

PDF files

  1. Supplementary Information (10.9M)

    This file contains Supplementary Figures 1-10, Supplementary Tables 1-4, a Supplementary Discussion and Supplementary References. The Supplementary Information provides additional background information to the insulin receptor system, images showing how the Fabs bind to the receptor constructs, images showing the assembly of the Complex D tetramer, an image showing the comparison of the conformations of insulin observed here with that of its receptor-free form and an image showing the implications for Site 2 binding. In addition, it provides protein production, purification, isothermal calorimetric and crystallographic detail.

Additional data